nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—osteoarthritis—Prednisone—prostate cancer	0.311	1	CpDpCtD
Sulindac—CYP1A1—prostate cancer	0.111	0.615	CbGaD
Sulindac—PTGS2—prostate cancer	0.0694	0.385	CbGaD
Sulindac—CYP1A1—Flutamide—prostate cancer	0.0393	0.159	CbGbCtD
Sulindac—ALB—Abiraterone—prostate cancer	0.0293	0.119	CbGbCtD
Sulindac—CYP1A1—Estrone—prostate cancer	0.0284	0.115	CbGbCtD
Sulindac—ALB—Estrone—prostate cancer	0.0212	0.0858	CbGbCtD
Sulindac—CYP1A2—Flutamide—prostate cancer	0.0175	0.071	CbGbCtD
Sulindac—CYP1A1—Estradiol—prostate cancer	0.0163	0.066	CbGbCtD
Sulindac—SLC22A6—Conjugated Estrogens—prostate cancer	0.0163	0.0659	CbGbCtD
Sulindac—CYP1A2—Estrone—prostate cancer	0.0127	0.0513	CbGbCtD
Sulindac—PTGS2—Etoposide—prostate cancer	0.0126	0.051	CbGbCtD
Sulindac—ALB—Estradiol—prostate cancer	0.0122	0.0493	CbGbCtD
Sulindac—PTGS1—Etoposide—prostate cancer	0.0106	0.0431	CbGbCtD
Sulindac—ALB—Prednisone—prostate cancer	0.0105	0.0424	CbGbCtD
Sulindac—CYP1A2—Conjugated Estrogens—prostate cancer	0.0083	0.0336	CbGbCtD
Sulindac—CYP1A2—Estradiol—prostate cancer	0.00728	0.0295	CbGbCtD
Sulindac—CYP1A2—Etoposide—prostate cancer	0.00476	0.0192	CbGbCtD
Sulindac—AKR1B1—prostate gland—prostate cancer	0.00248	0.0733	CbGeAlD
Sulindac—AKR1B1—seminal vesicle—prostate cancer	0.0021	0.062	CbGeAlD
Sulindac—PPARD—prostate gland—prostate cancer	0.00195	0.0576	CbGeAlD
Sulindac—AKR1B1—epithelium—prostate cancer	0.00183	0.0538	CbGeAlD
Sulindac—MAPK3—prostate gland—prostate cancer	0.0018	0.0531	CbGeAlD
Sulindac—AKR1B1—renal system—prostate cancer	0.00169	0.0499	CbGeAlD
Sulindac—AKR1B1—urethra—prostate cancer	0.00166	0.0491	CbGeAlD
Sulindac—CYP1A2—urine—prostate cancer	0.00157	0.0464	CbGeAlD
Sulindac—MAPK3—seminal vesicle—prostate cancer	0.00152	0.0449	CbGeAlD
Sulindac—MAPK3—epithelium—prostate cancer	0.00132	0.039	CbGeAlD
Sulindac—AKR1B1—bone marrow—prostate cancer	0.00128	0.0378	CbGeAlD
Sulindac—MAPK3—renal system—prostate cancer	0.00123	0.0362	CbGeAlD
Sulindac—MAPK3—urethra—prostate cancer	0.00121	0.0356	CbGeAlD
Sulindac—AKR1B1—testis—prostate cancer	0.00109	0.0323	CbGeAlD
Sulindac—MAPK3—bone marrow—prostate cancer	0.000928	0.0274	CbGeAlD
Sulindac—PPARD—testis—prostate cancer	0.00086	0.0254	CbGeAlD
Sulindac—MAPK3—testis—prostate cancer	0.000793	0.0234	CbGeAlD
Sulindac—AKR1B1—lymph node—prostate cancer	0.000793	0.0234	CbGeAlD
Sulindac—PPARD—lymph node—prostate cancer	0.000624	0.0184	CbGeAlD
Sulindac—MAPK3—lymph node—prostate cancer	0.000575	0.017	CbGeAlD
Sulindac—PTGS1—prostate gland—prostate cancer	0.000489	0.0144	CbGeAlD
Sulindac—PTGS2—prostate gland—prostate cancer	0.000468	0.0138	CbGeAlD
Sulindac—PTGS1—seminal vesicle—prostate cancer	0.000414	0.0122	CbGeAlD
Sulindac—CYP1A1—epithelium—prostate cancer	0.000409	0.0121	CbGeAlD
Sulindac—PTGS2—seminal vesicle—prostate cancer	0.000396	0.0117	CbGeAlD
Sulindac—CYP1A2—renal system—prostate cancer	0.000385	0.0114	CbGeAlD
Sulindac—CYP1A1—renal system—prostate cancer	0.00038	0.0112	CbGeAlD
Sulindac—ALB—testis—prostate cancer	0.000378	0.0112	CbGeAlD
Sulindac—CYP1A1—urethra—prostate cancer	0.000373	0.011	CbGeAlD
Sulindac—PTGS1—epithelium—prostate cancer	0.00036	0.0106	CbGeAlD
Sulindac—PTGS2—epithelium—prostate cancer	0.000344	0.0101	CbGeAlD
Sulindac—PTGS1—renal system—prostate cancer	0.000334	0.00984	CbGeAlD
Sulindac—PTGS2—renal system—prostate cancer	0.000319	0.0094	CbGeAlD
Sulindac—PTGS2—urethra—prostate cancer	0.000313	0.00924	CbGeAlD
Sulindac—ALB—lymph node—prostate cancer	0.000274	0.00809	CbGeAlD
Sulindac—PTGS2—bone marrow—prostate cancer	0.000241	0.00711	CbGeAlD
Sulindac—PTGS1—testis—prostate cancer	0.000216	0.00636	CbGeAlD
Sulindac—CYP1A1—lymph node—prostate cancer	0.000178	0.00525	CbGeAlD
Sulindac—PTGS1—lymph node—prostate cancer	0.000156	0.00461	CbGeAlD
Sulindac—PTGS2—lymph node—prostate cancer	0.000149	0.00441	CbGeAlD
Sulindac—Vision blurred—Prednisone—prostate cancer	3.88e-05	0.000354	CcSEcCtD
Sulindac—Feeling abnormal—Etoposide—prostate cancer	3.86e-05	0.000353	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—prostate cancer	3.85e-05	0.000352	CcSEcCtD
Sulindac—Diarrhoea—Mitoxantrone—prostate cancer	3.85e-05	0.000352	CcSEcCtD
Sulindac—Vomiting—Estradiol—prostate cancer	3.84e-05	0.000351	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—prostate cancer	3.84e-05	0.000351	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—prostate cancer	3.83e-05	0.00035	CcSEcCtD
Sulindac—Gastrointestinal pain—Etoposide—prostate cancer	3.83e-05	0.00035	CcSEcCtD
Sulindac—Shock—Docetaxel—prostate cancer	3.83e-05	0.00035	CcSEcCtD
Sulindac—Ill-defined disorder—Prednisone—prostate cancer	3.82e-05	0.000349	CcSEcCtD
Sulindac—Thrombocytopenia—Docetaxel—prostate cancer	3.81e-05	0.000348	CcSEcCtD
Sulindac—Rash—Estradiol—prostate cancer	3.81e-05	0.000348	CcSEcCtD
Sulindac—Dermatitis—Estradiol—prostate cancer	3.81e-05	0.000348	CcSEcCtD
Sulindac—Anaemia—Prednisone—prostate cancer	3.8e-05	0.000348	CcSEcCtD
Sulindac—Tachycardia—Docetaxel—prostate cancer	3.8e-05	0.000347	CcSEcCtD
Sulindac—Headache—Estradiol—prostate cancer	3.78e-05	0.000346	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	3.77e-05	0.000345	CcSEcCtD
Sulindac—Oedema—Capecitabine—prostate cancer	3.77e-05	0.000345	CcSEcCtD
Sulindac—Angioedema—Prednisone—prostate cancer	3.76e-05	0.000344	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—prostate cancer	3.74e-05	0.000342	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—prostate cancer	3.73e-05	0.000341	CcSEcCtD
Sulindac—Urticaria—Etoposide—prostate cancer	3.72e-05	0.00034	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—prostate cancer	3.71e-05	0.000339	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—prostate cancer	3.71e-05	0.000339	CcSEcCtD
Sulindac—Anorexia—Docetaxel—prostate cancer	3.71e-05	0.000339	CcSEcCtD
Sulindac—Malaise—Prednisone—prostate cancer	3.71e-05	0.000339	CcSEcCtD
Sulindac—Shock—Capecitabine—prostate cancer	3.71e-05	0.000339	CcSEcCtD
Sulindac—Body temperature increased—Etoposide—prostate cancer	3.7e-05	0.000339	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—prostate cancer	3.7e-05	0.000338	CcSEcCtD
Sulindac—Vertigo—Prednisone—prostate cancer	3.69e-05	0.000338	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—prostate cancer	3.69e-05	0.000338	CcSEcCtD
Sulindac—Thrombocytopenia—Capecitabine—prostate cancer	3.69e-05	0.000337	CcSEcCtD
Sulindac—Syncope—Prednisone—prostate cancer	3.69e-05	0.000337	CcSEcCtD
Sulindac—Tachycardia—Capecitabine—prostate cancer	3.68e-05	0.000336	CcSEcCtD
Sulindac—Sweating—Doxorubicin—prostate cancer	3.65e-05	0.000334	CcSEcCtD
Sulindac—Hyperhidrosis—Capecitabine—prostate cancer	3.64e-05	0.000333	CcSEcCtD
Sulindac—Hypotension—Docetaxel—prostate cancer	3.64e-05	0.000333	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—prostate cancer	3.63e-05	0.000332	CcSEcCtD
Sulindac—Loss of consciousness—Prednisone—prostate cancer	3.61e-05	0.000331	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—prostate cancer	3.59e-05	0.000328	CcSEcCtD
Sulindac—Anorexia—Capecitabine—prostate cancer	3.59e-05	0.000328	CcSEcCtD
Sulindac—Nausea—Estradiol—prostate cancer	3.59e-05	0.000328	CcSEcCtD
Sulindac—Vomiting—Mitoxantrone—prostate cancer	3.58e-05	0.000327	CcSEcCtD
Sulindac—Convulsion—Prednisone—prostate cancer	3.56e-05	0.000326	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—prostate cancer	3.56e-05	0.000326	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—prostate cancer	3.55e-05	0.000325	CcSEcCtD
Sulindac—Hypertension—Prednisone—prostate cancer	3.55e-05	0.000325	CcSEcCtD
Sulindac—Rash—Mitoxantrone—prostate cancer	3.55e-05	0.000325	CcSEcCtD
Sulindac—Dermatitis—Mitoxantrone—prostate cancer	3.55e-05	0.000324	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.55e-05	0.000324	CcSEcCtD
Sulindac—Headache—Mitoxantrone—prostate cancer	3.53e-05	0.000323	CcSEcCtD
Sulindac—Hypotension—Capecitabine—prostate cancer	3.52e-05	0.000322	CcSEcCtD
Sulindac—Insomnia—Docetaxel—prostate cancer	3.52e-05	0.000322	CcSEcCtD
Sulindac—Arthralgia—Prednisone—prostate cancer	3.5e-05	0.00032	CcSEcCtD
Sulindac—Myalgia—Prednisone—prostate cancer	3.5e-05	0.00032	CcSEcCtD
Sulindac—Paraesthesia—Docetaxel—prostate cancer	3.49e-05	0.00032	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—prostate cancer	3.49e-05	0.000319	CcSEcCtD
Sulindac—Dyspnoea—Docetaxel—prostate cancer	3.47e-05	0.000317	CcSEcCtD
Sulindac—Somnolence—Docetaxel—prostate cancer	3.46e-05	0.000316	CcSEcCtD
Sulindac—Discomfort—Prednisone—prostate cancer	3.46e-05	0.000316	CcSEcCtD
Sulindac—Hypersensitivity—Etoposide—prostate cancer	3.45e-05	0.000315	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—prostate cancer	3.44e-05	0.000315	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.43e-05	0.000314	CcSEcCtD
Sulindac—Flushing—Epirubicin—prostate cancer	3.43e-05	0.000314	CcSEcCtD
Sulindac—Dyspepsia—Docetaxel—prostate cancer	3.43e-05	0.000313	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—prostate cancer	3.42e-05	0.000313	CcSEcCtD
Sulindac—Insomnia—Capecitabine—prostate cancer	3.41e-05	0.000312	CcSEcCtD
Sulindac—Paraesthesia—Capecitabine—prostate cancer	3.38e-05	0.000309	CcSEcCtD
Sulindac—Decreased appetite—Docetaxel—prostate cancer	3.38e-05	0.000309	CcSEcCtD
Sulindac—Asthenia—Etoposide—prostate cancer	3.36e-05	0.000307	CcSEcCtD
Sulindac—Dyspnoea—Capecitabine—prostate cancer	3.36e-05	0.000307	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisone—prostate cancer	3.36e-05	0.000307	CcSEcCtD
Sulindac—Oedema—Prednisone—prostate cancer	3.36e-05	0.000307	CcSEcCtD
Sulindac—Fatigue—Docetaxel—prostate cancer	3.35e-05	0.000307	CcSEcCtD
Sulindac—Nausea—Mitoxantrone—prostate cancer	3.34e-05	0.000306	CcSEcCtD
Sulindac—Constipation—Docetaxel—prostate cancer	3.33e-05	0.000304	CcSEcCtD
Sulindac—Dyspepsia—Capecitabine—prostate cancer	3.32e-05	0.000303	CcSEcCtD
Sulindac—Chills—Epirubicin—prostate cancer	3.31e-05	0.000303	CcSEcCtD
Sulindac—Pruritus—Etoposide—prostate cancer	3.31e-05	0.000303	CcSEcCtD
Sulindac—Shock—Prednisone—prostate cancer	3.3e-05	0.000302	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—prostate cancer	3.3e-05	0.000302	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—prostate cancer	3.29e-05	0.000301	CcSEcCtD
Sulindac—Tachycardia—Prednisone—prostate cancer	3.28e-05	0.0003	CcSEcCtD
Sulindac—Decreased appetite—Capecitabine—prostate cancer	3.27e-05	0.0003	CcSEcCtD
Sulindac—Alopecia—Epirubicin—prostate cancer	3.26e-05	0.000299	CcSEcCtD
Sulindac—Fatigue—Capecitabine—prostate cancer	3.25e-05	0.000297	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisone—prostate cancer	3.24e-05	0.000297	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—prostate cancer	3.23e-05	0.000296	CcSEcCtD
Sulindac—Constipation—Capecitabine—prostate cancer	3.22e-05	0.000295	CcSEcCtD
Sulindac—Feeling abnormal—Docetaxel—prostate cancer	3.21e-05	0.000293	CcSEcCtD
Sulindac—Diarrhoea—Etoposide—prostate cancer	3.2e-05	0.000293	CcSEcCtD
Sulindac—Anorexia—Prednisone—prostate cancer	3.2e-05	0.000293	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—prostate cancer	3.19e-05	0.000291	CcSEcCtD
Sulindac—Gastrointestinal pain—Docetaxel—prostate cancer	3.18e-05	0.000291	CcSEcCtD
Sulindac—Flushing—Doxorubicin—prostate cancer	3.17e-05	0.00029	CcSEcCtD
Sulindac—Flatulence—Epirubicin—prostate cancer	3.17e-05	0.00029	CcSEcCtD
Sulindac—Tension—Epirubicin—prostate cancer	3.16e-05	0.000289	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—prostate cancer	3.15e-05	0.000288	CcSEcCtD
Sulindac—Nervousness—Epirubicin—prostate cancer	3.12e-05	0.000286	CcSEcCtD
Sulindac—Feeling abnormal—Capecitabine—prostate cancer	3.1e-05	0.000284	CcSEcCtD
Sulindac—Dizziness—Etoposide—prostate cancer	3.1e-05	0.000283	CcSEcCtD
Sulindac—Gastrointestinal pain—Capecitabine—prostate cancer	3.08e-05	0.000282	CcSEcCtD
Sulindac—Body temperature increased—Docetaxel—prostate cancer	3.08e-05	0.000281	CcSEcCtD
Sulindac—Chills—Doxorubicin—prostate cancer	3.07e-05	0.00028	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Prednisone—prostate cancer	3.06e-05	0.00028	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—prostate cancer	3.05e-05	0.000279	CcSEcCtD
Sulindac—Insomnia—Prednisone—prostate cancer	3.04e-05	0.000278	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—prostate cancer	3.03e-05	0.000277	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—prostate cancer	3.02e-05	0.000276	CcSEcCtD
Sulindac—Paraesthesia—Prednisone—prostate cancer	3.01e-05	0.000276	CcSEcCtD
Sulindac—Urticaria—Capecitabine—prostate cancer	2.99e-05	0.000274	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—prostate cancer	2.98e-05	0.000273	CcSEcCtD
Sulindac—Body temperature increased—Capecitabine—prostate cancer	2.98e-05	0.000272	CcSEcCtD
Sulindac—Vomiting—Etoposide—prostate cancer	2.98e-05	0.000272	CcSEcCtD
Sulindac—Anaemia—Epirubicin—prostate cancer	2.97e-05	0.000272	CcSEcCtD
Sulindac—Dyspepsia—Prednisone—prostate cancer	2.95e-05	0.00027	CcSEcCtD
Sulindac—Rash—Etoposide—prostate cancer	2.95e-05	0.00027	CcSEcCtD
Sulindac—Dermatitis—Etoposide—prostate cancer	2.95e-05	0.00027	CcSEcCtD
Sulindac—Headache—Etoposide—prostate cancer	2.93e-05	0.000268	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—prostate cancer	2.93e-05	0.000268	CcSEcCtD
Sulindac—Tension—Doxorubicin—prostate cancer	2.92e-05	0.000267	CcSEcCtD
Sulindac—Decreased appetite—Prednisone—prostate cancer	2.92e-05	0.000267	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—prostate cancer	2.91e-05	0.000266	CcSEcCtD
Sulindac—Malaise—Epirubicin—prostate cancer	2.9e-05	0.000265	CcSEcCtD
Sulindac—Fatigue—Prednisone—prostate cancer	2.89e-05	0.000265	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—prostate cancer	2.89e-05	0.000264	CcSEcCtD
Sulindac—Vertigo—Epirubicin—prostate cancer	2.89e-05	0.000264	CcSEcCtD
Sulindac—Syncope—Epirubicin—prostate cancer	2.88e-05	0.000264	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—prostate cancer	2.88e-05	0.000263	CcSEcCtD
Sulindac—Constipation—Prednisone—prostate cancer	2.87e-05	0.000262	CcSEcCtD
Sulindac—Hypersensitivity—Docetaxel—prostate cancer	2.87e-05	0.000262	CcSEcCtD
Sulindac—Palpitations—Epirubicin—prostate cancer	2.84e-05	0.00026	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—prostate cancer	2.83e-05	0.000258	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—prostate cancer	2.8e-05	0.000256	CcSEcCtD
Sulindac—Asthenia—Docetaxel—prostate cancer	2.79e-05	0.000255	CcSEcCtD
Sulindac—Convulsion—Epirubicin—prostate cancer	2.79e-05	0.000255	CcSEcCtD
Sulindac—Nausea—Etoposide—prostate cancer	2.78e-05	0.000254	CcSEcCtD
Sulindac—Hypertension—Epirubicin—prostate cancer	2.78e-05	0.000254	CcSEcCtD
Sulindac—Hypersensitivity—Capecitabine—prostate cancer	2.78e-05	0.000254	CcSEcCtD
Sulindac—Feeling abnormal—Prednisone—prostate cancer	2.77e-05	0.000253	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—prostate cancer	2.76e-05	0.000252	CcSEcCtD
Sulindac—Pruritus—Docetaxel—prostate cancer	2.75e-05	0.000252	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—prostate cancer	2.75e-05	0.000252	CcSEcCtD
Sulindac—Gastrointestinal pain—Prednisone—prostate cancer	2.74e-05	0.000251	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—prostate cancer	2.74e-05	0.00025	CcSEcCtD
Sulindac—Chest pain—Epirubicin—prostate cancer	2.74e-05	0.00025	CcSEcCtD
Sulindac—Myalgia—Epirubicin—prostate cancer	2.74e-05	0.00025	CcSEcCtD
Sulindac—Discomfort—Epirubicin—prostate cancer	2.71e-05	0.000247	CcSEcCtD
Sulindac—Asthenia—Capecitabine—prostate cancer	2.7e-05	0.000247	CcSEcCtD
Sulindac—Malaise—Doxorubicin—prostate cancer	2.68e-05	0.000245	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—prostate cancer	2.67e-05	0.000244	CcSEcCtD
Sulindac—Syncope—Doxorubicin—prostate cancer	2.67e-05	0.000244	CcSEcCtD
Sulindac—Urticaria—Prednisone—prostate cancer	2.67e-05	0.000244	CcSEcCtD
Sulindac—Pruritus—Capecitabine—prostate cancer	2.67e-05	0.000244	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—prostate cancer	2.66e-05	0.000244	CcSEcCtD
Sulindac—Diarrhoea—Docetaxel—prostate cancer	2.66e-05	0.000243	CcSEcCtD
Sulindac—Body temperature increased—Prednisone—prostate cancer	2.65e-05	0.000243	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—prostate cancer	2.63e-05	0.00024	CcSEcCtD
Sulindac—Oedema—Epirubicin—prostate cancer	2.62e-05	0.00024	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—prostate cancer	2.62e-05	0.00024	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—prostate cancer	2.62e-05	0.000239	CcSEcCtD
Sulindac—Shock—Epirubicin—prostate cancer	2.58e-05	0.000236	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—prostate cancer	2.58e-05	0.000236	CcSEcCtD
Sulindac—Diarrhoea—Capecitabine—prostate cancer	2.58e-05	0.000236	CcSEcCtD
Sulindac—Dizziness—Docetaxel—prostate cancer	2.57e-05	0.000235	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—prostate cancer	2.57e-05	0.000235	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—prostate cancer	2.57e-05	0.000235	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—prostate cancer	2.56e-05	0.000234	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—prostate cancer	2.54e-05	0.000232	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—prostate cancer	2.53e-05	0.000232	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—prostate cancer	2.53e-05	0.000232	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—prostate cancer	2.53e-05	0.000232	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—prostate cancer	2.5e-05	0.000229	CcSEcCtD
Sulindac—Anorexia—Epirubicin—prostate cancer	2.5e-05	0.000229	CcSEcCtD
Sulindac—Dizziness—Capecitabine—prostate cancer	2.49e-05	0.000228	CcSEcCtD
Sulindac—Vomiting—Docetaxel—prostate cancer	2.47e-05	0.000226	CcSEcCtD
Sulindac—Hypersensitivity—Prednisone—prostate cancer	2.47e-05	0.000226	CcSEcCtD
Sulindac—Rash—Docetaxel—prostate cancer	2.45e-05	0.000224	CcSEcCtD
Sulindac—Hypotension—Epirubicin—prostate cancer	2.45e-05	0.000224	CcSEcCtD
Sulindac—Dermatitis—Docetaxel—prostate cancer	2.45e-05	0.000224	CcSEcCtD
Sulindac—Headache—Docetaxel—prostate cancer	2.44e-05	0.000223	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—prostate cancer	2.43e-05	0.000222	CcSEcCtD
Sulindac—Oedema—Doxorubicin—prostate cancer	2.43e-05	0.000222	CcSEcCtD
Sulindac—Asthenia—Prednisone—prostate cancer	2.41e-05	0.00022	CcSEcCtD
Sulindac—Vomiting—Capecitabine—prostate cancer	2.4e-05	0.000219	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.39e-05	0.000219	CcSEcCtD
Sulindac—Shock—Doxorubicin—prostate cancer	2.39e-05	0.000219	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—prostate cancer	2.38e-05	0.000217	CcSEcCtD
Sulindac—Rash—Capecitabine—prostate cancer	2.38e-05	0.000217	CcSEcCtD
Sulindac—Pruritus—Prednisone—prostate cancer	2.37e-05	0.000217	CcSEcCtD
Sulindac—Insomnia—Epirubicin—prostate cancer	2.37e-05	0.000217	CcSEcCtD
Sulindac—Dermatitis—Capecitabine—prostate cancer	2.37e-05	0.000217	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—prostate cancer	2.37e-05	0.000217	CcSEcCtD
Sulindac—Headache—Capecitabine—prostate cancer	2.36e-05	0.000216	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—prostate cancer	2.36e-05	0.000216	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—prostate cancer	2.35e-05	0.000215	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—prostate cancer	2.34e-05	0.000214	CcSEcCtD
Sulindac—Somnolence—Epirubicin—prostate cancer	2.33e-05	0.000213	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—prostate cancer	2.31e-05	0.000212	CcSEcCtD
Sulindac—Nausea—Docetaxel—prostate cancer	2.31e-05	0.000211	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—prostate cancer	2.31e-05	0.000211	CcSEcCtD
Sulindac—Diarrhoea—Prednisone—prostate cancer	2.3e-05	0.00021	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—prostate cancer	2.28e-05	0.000209	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—prostate cancer	2.27e-05	0.000208	CcSEcCtD
Sulindac—Fatigue—Epirubicin—prostate cancer	2.26e-05	0.000207	CcSEcCtD
Sulindac—Constipation—Epirubicin—prostate cancer	2.24e-05	0.000205	CcSEcCtD
Sulindac—Nausea—Capecitabine—prostate cancer	2.24e-05	0.000205	CcSEcCtD
Sulindac—Dizziness—Prednisone—prostate cancer	2.22e-05	0.000203	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.21e-05	0.000202	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—prostate cancer	2.2e-05	0.000201	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—prostate cancer	2.18e-05	0.000199	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—prostate cancer	2.17e-05	0.000198	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—prostate cancer	2.16e-05	0.000198	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—prostate cancer	2.16e-05	0.000197	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—prostate cancer	2.15e-05	0.000196	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—prostate cancer	2.14e-05	0.000196	CcSEcCtD
Sulindac—Vomiting—Prednisone—prostate cancer	2.13e-05	0.000195	CcSEcCtD
Sulindac—Rash—Prednisone—prostate cancer	2.12e-05	0.000194	CcSEcCtD
Sulindac—Dermatitis—Prednisone—prostate cancer	2.11e-05	0.000193	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—prostate cancer	2.11e-05	0.000193	CcSEcCtD
Sulindac—Headache—Prednisone—prostate cancer	2.1e-05	0.000192	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—prostate cancer	2.09e-05	0.000191	CcSEcCtD
Sulindac—Urticaria—Epirubicin—prostate cancer	2.09e-05	0.000191	CcSEcCtD
Sulindac—Constipation—Doxorubicin—prostate cancer	2.08e-05	0.00019	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—prostate cancer	2.07e-05	0.00019	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—prostate cancer	2e-05	0.000183	CcSEcCtD
Sulindac—Nausea—Prednisone—prostate cancer	1.99e-05	0.000182	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—prostate cancer	1.99e-05	0.000182	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—prostate cancer	1.93e-05	0.000177	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—prostate cancer	1.93e-05	0.000176	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—prostate cancer	1.92e-05	0.000176	CcSEcCtD
Sulindac—Asthenia—Epirubicin—prostate cancer	1.88e-05	0.000172	CcSEcCtD
Sulindac—Pruritus—Epirubicin—prostate cancer	1.86e-05	0.00017	CcSEcCtD
Sulindac—Diarrhoea—Epirubicin—prostate cancer	1.8e-05	0.000164	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—prostate cancer	1.79e-05	0.000164	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—prostate cancer	1.74e-05	0.000159	CcSEcCtD
Sulindac—Dizziness—Epirubicin—prostate cancer	1.74e-05	0.000159	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—prostate cancer	1.72e-05	0.000157	CcSEcCtD
Sulindac—Vomiting—Epirubicin—prostate cancer	1.67e-05	0.000153	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—prostate cancer	1.66e-05	0.000152	CcSEcCtD
Sulindac—Rash—Epirubicin—prostate cancer	1.65e-05	0.000151	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—prostate cancer	1.65e-05	0.000151	CcSEcCtD
Sulindac—Headache—Epirubicin—prostate cancer	1.64e-05	0.00015	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—prostate cancer	1.61e-05	0.000147	CcSEcCtD
Sulindac—Nausea—Epirubicin—prostate cancer	1.56e-05	0.000143	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—prostate cancer	1.54e-05	0.000141	CcSEcCtD
Sulindac—Rash—Doxorubicin—prostate cancer	1.53e-05	0.00014	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—prostate cancer	1.53e-05	0.00014	CcSEcCtD
Sulindac—Headache—Doxorubicin—prostate cancer	1.52e-05	0.000139	CcSEcCtD
Sulindac—Nausea—Doxorubicin—prostate cancer	1.44e-05	0.000132	CcSEcCtD
Sulindac—ALB—Metabolism—TH—prostate cancer	1.55e-06	1.31e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.54e-06	1.3e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.54e-06	1.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IRS1—prostate cancer	1.53e-06	1.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGF—prostate cancer	1.53e-06	1.3e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP3A4—prostate cancer	1.53e-06	1.29e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CAV1—prostate cancer	1.53e-06	1.29e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.52e-06	1.29e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SULT2A1—prostate cancer	1.52e-06	1.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EP300—prostate cancer	1.52e-06	1.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CTNNB1—prostate cancer	1.51e-06	1.27e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1B1—prostate cancer	1.51e-06	1.27e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TYMS—prostate cancer	1.5e-06	1.27e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—RXRA—prostate cancer	1.5e-06	1.27e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HIF1A—prostate cancer	1.5e-06	1.27e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MED12—prostate cancer	1.49e-06	1.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GSK3B—prostate cancer	1.49e-06	1.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTM1—prostate cancer	1.49e-06	1.26e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GNG5—prostate cancer	1.48e-06	1.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—SRC—prostate cancer	1.47e-06	1.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1A—prostate cancer	1.47e-06	1.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—INS—prostate cancer	1.47e-06	1.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—prostate cancer	1.47e-06	1.24e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—LPL—prostate cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GGT1—prostate cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.46e-06	1.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CAV1—prostate cancer	1.45e-06	1.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—COMT—prostate cancer	1.44e-06	1.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CREBBP—prostate cancer	1.44e-06	1.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTP1—prostate cancer	1.44e-06	1.21e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—NCOA1—prostate cancer	1.44e-06	1.21e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOA3—prostate cancer	1.43e-06	1.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—prostate cancer	1.42e-06	1.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IGF1—prostate cancer	1.42e-06	1.2e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP19A1—prostate cancer	1.42e-06	1.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—prostate cancer	1.41e-06	1.2e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ITPR1—prostate cancer	1.41e-06	1.2e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP1A1—prostate cancer	1.41e-06	1.19e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.4e-06	1.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EP300—prostate cancer	1.4e-06	1.18e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ERCC2—prostate cancer	1.4e-06	1.18e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—EP300—prostate cancer	1.39e-06	1.18e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CG—prostate cancer	1.39e-06	1.18e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.39e-06	1.18e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—prostate cancer	1.39e-06	1.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAP2K1—prostate cancer	1.37e-06	1.16e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—RXRA—prostate cancer	1.37e-06	1.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CD—prostate cancer	1.36e-06	1.15e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HPGDS—prostate cancer	1.36e-06	1.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—SRC—prostate cancer	1.36e-06	1.15e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BAD—prostate cancer	1.36e-06	1.15e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2C19—prostate cancer	1.35e-06	1.14e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SRC—prostate cancer	1.35e-06	1.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SERPINE1—prostate cancer	1.35e-06	1.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—prostate cancer	1.34e-06	1.13e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TYMS—prostate cancer	1.34e-06	1.13e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.33e-06	1.12e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTT1—prostate cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ACHE—prostate cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTM1—prostate cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APC—prostate cancer	1.32e-06	1.12e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—prostate cancer	1.32e-06	1.11e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—INS—prostate cancer	1.32e-06	1.11e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—COMT—prostate cancer	1.32e-06	1.11e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—MTHFR—prostate cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—prostate cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—prostate cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTP1—prostate cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGF2—prostate cancer	1.31e-06	1.11e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2A6—prostate cancer	1.31e-06	1.1e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IRS1—prostate cancer	1.3e-06	1.1e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGF—prostate cancer	1.3e-06	1.1e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.3e-06	1.1e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—LPL—prostate cancer	1.3e-06	1.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—prostate cancer	1.29e-06	1.09e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CREBBP—prostate cancer	1.29e-06	1.09e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARA—prostate cancer	1.29e-06	1.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NOS3—prostate cancer	1.29e-06	1.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ITPR1—prostate cancer	1.29e-06	1.09e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKR1C3—prostate cancer	1.27e-06	1.07e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.27e-06	1.07e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—GSK3B—prostate cancer	1.27e-06	1.07e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PRKACB—prostate cancer	1.26e-06	1.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—JAK2—prostate cancer	1.25e-06	1.06e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP17A1—prostate cancer	1.25e-06	1.06e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—INS—prostate cancer	1.25e-06	1.06e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ERCC2—prostate cancer	1.24e-06	1.05e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.23e-06	1.04e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—prostate cancer	1.23e-06	1.04e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CD—prostate cancer	1.22e-06	1.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MDM2—prostate cancer	1.22e-06	1.03e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CREBBP—prostate cancer	1.22e-06	1.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—prostate cancer	1.22e-06	1.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—prostate cancer	1.22e-06	1.03e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TYMS—prostate cancer	1.22e-06	1.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—prostate cancer	1.22e-06	1.03e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CAV1—prostate cancer	1.21e-06	1.03e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—prostate cancer	1.21e-06	1.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB2—prostate cancer	1.21e-06	1.02e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTM1—prostate cancer	1.2e-06	1.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—prostate cancer	1.19e-06	1.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOA2—prostate cancer	1.19e-06	1.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CB—prostate cancer	1.19e-06	1.01e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—LPL—prostate cancer	1.18e-06	9.99e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAP2K1—prostate cancer	1.17e-06	9.87e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—MTHFR—prostate cancer	1.17e-06	9.86e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CD—prostate cancer	1.16e-06	9.8e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.16e-06	9.79e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NOS3—prostate cancer	1.15e-06	9.77e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—SERPINE1—prostate cancer	1.15e-06	9.7e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARA—prostate cancer	1.14e-06	9.68e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL8—prostate cancer	1.14e-06	9.67e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1A1—prostate cancer	1.14e-06	9.65e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC5A5—prostate cancer	1.14e-06	9.61e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—ERCC2—prostate cancer	1.13e-06	9.57e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—prostate cancer	1.13e-06	9.53e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—prostate cancer	1.12e-06	9.49e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—prostate cancer	1.12e-06	9.47e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1B—prostate cancer	1.12e-06	9.44e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.11e-06	9.39e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGF2—prostate cancer	1.11e-06	9.39e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CG—prostate cancer	1.1e-06	9.34e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NQO1—prostate cancer	1.1e-06	9.29e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS3—prostate cancer	1.09e-06	9.26e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—prostate cancer	1.09e-06	9.25e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—prostate cancer	1.09e-06	9.24e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—prostate cancer	1.09e-06	9.19e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TH—prostate cancer	1.08e-06	9.15e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CAV1—prostate cancer	1.08e-06	9.1e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.08e-06	9.09e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.07e-06	9.06e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CB—prostate cancer	1.07e-06	9.01e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.07e-06	9.01e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—prostate cancer	1.07e-06	9.01e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—JAK2—prostate cancer	1.06e-06	9e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—MTHFR—prostate cancer	1.06e-06	8.99e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—prostate cancer	1.06e-06	8.93e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CTNNB1—prostate cancer	1.05e-06	8.92e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.05e-06	8.9e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—INS—prostate cancer	1.05e-06	8.84e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARA—prostate cancer	1.04e-06	8.82e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MDM2—prostate cancer	1.04e-06	8.78e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—prostate cancer	1.04e-06	8.76e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—prostate cancer	1.03e-06	8.75e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1A—prostate cancer	1.03e-06	8.71e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—prostate cancer	1.03e-06	8.7e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—prostate cancer	1.03e-06	8.69e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.03e-06	8.69e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CREBBP—prostate cancer	1.02e-06	8.66e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB2—prostate cancer	1.02e-06	8.66e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GGT1—prostate cancer	1.02e-06	8.62e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CB—prostate cancer	1.01e-06	8.54e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOA1—prostate cancer	1e-06	8.49e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—prostate cancer	1e-06	8.48e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—prostate cancer	9.96e-07	8.42e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—prostate cancer	9.93e-07	8.4e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP19A1—prostate cancer	9.9e-07	8.37e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—CAV1—prostate cancer	9.81e-07	8.29e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EP300—prostate cancer	9.8e-07	8.29e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CG—prostate cancer	9.8e-07	8.29e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CD—prostate cancer	9.71e-07	8.21e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—RXRA—prostate cancer	9.55e-07	8.08e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SRC—prostate cancer	9.53e-07	8.06e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1B—prostate cancer	9.48e-07	8.02e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.37e-07	7.92e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	9.29e-07	7.86e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—prostate cancer	9.29e-07	7.85e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—INS—prostate cancer	9.28e-07	7.85e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—prostate cancer	9.21e-07	7.79e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—COMT—prostate cancer	9.2e-07	7.78e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—prostate cancer	9.19e-07	7.78e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—prostate cancer	9.17e-07	7.76e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NOS3—prostate cancer	9.17e-07	7.75e-06	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—prostate cancer	9.16e-07	7.75e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTP1—prostate cancer	9.16e-07	7.74e-06	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—prostate cancer	9.11e-07	7.71e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CREBBP—prostate cancer	9.09e-07	7.68e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ITPR1—prostate cancer	9.01e-07	7.62e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CTNNB1—prostate cancer	8.96e-07	7.58e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CG—prostate cancer	8.93e-07	7.56e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.86e-07	7.49e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—EP300—prostate cancer	8.78e-07	7.43e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1A—prostate cancer	8.75e-07	7.4e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—prostate cancer	8.73e-07	7.38e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CD—prostate cancer	8.62e-07	7.29e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—prostate cancer	8.54e-07	7.23e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—prostate cancer	8.52e-07	7.21e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TYMS—prostate cancer	8.51e-07	7.2e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CB—prostate cancer	8.46e-07	7.16e-06	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—prostate cancer	8.46e-07	7.15e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—INS—prostate cancer	8.46e-07	7.15e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTM1—prostate cancer	8.42e-07	7.12e-06	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—prostate cancer	8.41e-07	7.11e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—prostate cancer	8.36e-07	7.07e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—EP300—prostate cancer	8.33e-07	7.04e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—CREBBP—prostate cancer	8.28e-07	7e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—LPL—prostate cancer	8.26e-07	6.99e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NOS3—prostate cancer	8.14e-07	6.88e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—SRC—prostate cancer	8.1e-07	6.85e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1A1—prostate cancer	7.98e-07	6.75e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ERCC2—prostate cancer	7.91e-07	6.69e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—prostate cancer	7.89e-07	6.68e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CD—prostate cancer	7.85e-07	6.64e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—prostate cancer	7.81e-07	6.6e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CB—prostate cancer	7.51e-07	6.35e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—prostate cancer	7.44e-07	6.29e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MTHFR—prostate cancer	7.44e-07	6.29e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—NOS3—prostate cancer	7.42e-07	6.27e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—prostate cancer	7.31e-07	6.18e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARA—prostate cancer	7.3e-07	6.17e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—prostate cancer	7.26e-07	6.14e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—prostate cancer	7.25e-07	6.13e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—prostate cancer	7.24e-07	6.12e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—prostate cancer	7.1e-07	6e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—prostate cancer	7.02e-07	5.93e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—EP300—prostate cancer	6.97e-07	5.9e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CAV1—prostate cancer	6.86e-07	5.8e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CB—prostate cancer	6.85e-07	5.79e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—prostate cancer	6.78e-07	5.74e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—prostate cancer	6.7e-07	5.67e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.55e-07	5.54e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—prostate cancer	6.5e-07	5.49e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—prostate cancer	6.49e-07	5.49e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—prostate cancer	6.42e-07	5.43e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CG—prostate cancer	6.25e-07	5.28e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—EP300—prostate cancer	6.19e-07	5.23e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—prostate cancer	6.16e-07	5.21e-06	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—prostate cancer	5.92e-07	5.01e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—prostate cancer	5.92e-07	5e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—INS—prostate cancer	5.92e-07	5e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CREBBP—prostate cancer	5.79e-07	4.9e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—EP300—prostate cancer	5.64e-07	4.77e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CD—prostate cancer	5.49e-07	4.65e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—prostate cancer	5.45e-07	4.61e-06	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—prostate cancer	5.31e-07	4.49e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NOS3—prostate cancer	5.19e-07	4.39e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—prostate cancer	5.16e-07	4.36e-06	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—prostate cancer	5.03e-07	4.26e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CB—prostate cancer	4.79e-07	4.05e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—prostate cancer	4.74e-07	4.01e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—prostate cancer	4.58e-07	3.87e-06	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—prostate cancer	4.21e-07	3.56e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—prostate cancer	4.17e-07	3.53e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—prostate cancer	4.14e-07	3.5e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—EP300—prostate cancer	3.95e-07	3.34e-06	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—prostate cancer	3.74e-07	3.16e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—prostate cancer	3.41e-07	2.88e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—prostate cancer	2.92e-07	2.47e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—prostate cancer	2.38e-07	2.02e-06	CbGpPWpGaD
